- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears New 7T MRI System from Siemens Healthineers
Offering improved image clarity capable of capturing details of subtle pathology, the Magnetom Terra.X 7T MRI system reportedly features the first eight-channel parallel transmit architecture for clinical use.
The Magnetom Terra.X., a new 7T magnetic resonance imaging (MRI) system, has garnered 510(k) clearance from the Food and Drug Administration (FDA).
A second-generation successor to the Magnetom Terra, the Magnetom Terra.X system has a number of attributes to provide enhanced 7T imaging, according to Siemens Healthineers, the manufacturer of Magnetom Terra.X.
The Magnetom Terra.X system, recently cleared by the FDA, has a number of features including the first eight-channel parallel transmit architecture for clinical use, according to Siemens Healthineers, the manufacturer of the 7T MRI system. (Image courtesy of Siemens Healthineers.)
The company said key features of the device include:
• the first eight-channel parallel transmit architecture for clinical use;
• deep learning image reconstruction specifically geared to 7T;
• improved diffusion imaging via a high-performance gradient system; and
• accelerated image acquisition capabilities that can facilitate high-resolution brain and knee exams in less than 20 minutes.
“The MAGNETOM Terra.X builds on our engineering achievements as pioneers in 7T MRI by providing the ultra-high-field community with the necessary tools to offer higher-quality patient care not just in neurological imaging, but also in the knee,” said Katie Grant, vice president of magnetic resonance at Siemens Healthineers North America.
Siemens Healthineers added that the FDA clearance includes upgrades of installed Magnetom Terra systems to the Magnetom Terra.X.
Emerging MRI Scoring System May Help Predict Recurrent and Metastatic Hepatocellular Carcinoma
February 12th 2025Preoperative use of the scoring system for gadoxetic acid-enhanced MRI demonstrated an average AUC of 85 percent and average specificity of 89 percent in external validation cohorts for pathologic features of hepatocellular carcinoma.
Comparative AI Study Shows Merits of RapidAI LVO Software in Stroke Detection
February 6th 2025The Rapid LVO AI software detected 33 percent more cases of large vessel occlusion (LVO) on computed tomography angiography (CTA) than Viz LVO AI software, according to a new comparative study presented at the International Stroke Conference (ISC).
